Analytical Data
-
基因名
Bcl-XL
-
简介
Bcl-XL protein forms heterodimers with BAX, BAK, or BCL2, but its antiapoptotic activity does not require heterodimerization with BAX. Bcl-XL Protein, Mouse (C-His) is the recombinant mouse-derived Bcl-XL, expressed by E. coli , with C-6*His labeled tag.
- Application
-
别名
Bcl-2-like protein 1; Bcl2-L-1; Apoptosis regulator Bcl-X; Bclx
-
种属
Mouse
-
表达系统
E. coli
-
标签
C-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q64373-1
-
表达区间
M1-R212
-
氨基酸序列
MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEETEAERETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIASWMATYLNDHLEPWIQENGGWDTFVDLYGNNAAAESRKGQERFNR
-
蛋白长度
Partial
-
分子量
27 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Bcl-XL, a member of the Bcl-2 family of proteins, plays a crucial role in the regulation of apoptosis, or programmed cell death, which is essential for maintaining cellular homeostasis and tissue integrity. Dysregulation of Bcl-XL is implicated in various diseases, including cancers, where its overexpression can lead to tumor survival and resistance to therapy. This has sparked significant interest in Bcl-XL as a potential therapeutic target. The study of recombinant Bcl-XL protein has enabled researchers to explore its functional mechanisms, interaction with other apoptosis regulators, and its role in cellular signaling pathways. By producing recombinant Bcl-XL in vitro, scientists can investigate its structure-function relationships and develop specific inhibitors that may restore apoptotic processes in cancer cells. This research has yielded insights into the therapeutic potential of Bcl-XL antagonists, paving the way for novel cancer treatments that aim to enhance the efficacy of existing therapies and overcome resistance mechanisms. The ongoing exploration of Bcl-XL’s biological roles and its clinical significance continues to be a promising avenue in the fight against malignancies and other pathologies linked to aberrant apoptosis.
